In a landmark development for oncology, a major UK-led clinical trial has demonstrated that tailoring treatment to the specific genetic profile of a patient’s cancer can significantly extend survival for those with the most aggressive forms of multiple myeloma. The findings, published in The Lancet Oncology, represent a shift in the treatment paradigm, moving away from a "one-size-fits-all" approach toward a precision medicine model that could save thousands of lives annually.
The OPTIMUM (MUKnine) trial, conducted by The Institute of Cancer Research (ICR), London, alongside the University of Leeds and The Royal Marsden NHS Foundation Trust, suggests that by identifying aggressive disease early through molecular diagnostics, clinicians can intervene with intensified, risk-adapted therapies. For patients previously facing a prognosis of rapid relapse and poor outcomes, these results offer a new, durable lease on life.
The Challenge of Aggressive Myeloma
Multiple myeloma, a cancer of the plasma cells, affects approximately 5,900 people in the UK each year. While advancements in modern medicine have pushed the five-year survival rate for the general myeloma population to over 50%, a persistent subgroup remains particularly vulnerable. Roughly 20% to 25% of patients present with aggressive, high-risk disease that often fails to respond to conventional therapies, leading to early relapse and significantly shorter life expectancies.
Historically, these patients have been treated with standard protocols, often unaware of the specific genetic abnormalities driving their cancer. The OPTIMUM trial sought to change this by testing whether early identification of high-risk markers followed by an intensified, personalized drug regimen could improve long-term outcomes.
Chronology of the OPTIMUM Trial
The journey toward these results has been defined by rigorous scientific collaboration and long-term observation:
- Initial Design: The OPTIMUM (MUKnine) trial was conceived to evaluate the efficacy of an intensified drug regimen compared to standard care. The trial utilized a combination of five licensed medicines already available within the NHS: daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone.
- The Intervention: Rather than standard dosing, the trial employed an intensified upfront strategy, maintaining combination therapy for as long as the disease remained controlled.
- Early Findings: Initial analyses, funded by Myeloma UK and The David Forbes Nixon Foundation, provided early signals that high-risk patients were responding more favorably to this intensified protocol than they had to conventional treatments.
- The Long-Term Data: Recent follow-up data—the culmination of approximately six years of monitoring—has now confirmed the durability of these early results. The extended analysis provides the robust evidence needed to advocate for systemic changes in how myeloma is diagnosed and managed.
Supporting Data: A Statistical Leap in Survival
The data emerging from the OPTIMUM trial is stark and compelling. When comparing participants in the trial to a matched external control group from the Myeloma XI trial, the divergence in survival outcomes is significant.
At the six-year mark, approximately 69.1% of patients on the OPTIMUM trial were still alive. In contrast, patients receiving standard therapy saw a survival rate of approximately 40%. The difference is even more pronounced when examining progression-free survival (PFS). Over half of the trial participants (53.8%) remained progression-free at six years, compared to fewer than one in five (17.6%) in the control group.
Perhaps most tellingly, the median survival for patients on standard therapy was calculated at roughly 57 months—just under five years. For those on the OPTIMUM trial, the median survival had not been reached by the end of the follow-up period, indicating a substantial and sustained therapeutic benefit.
Identifying the "Hidden" High-Risk Patient
A critical component of the trial’s success was the use of the MMProfiler SKY92 test, a gene expression profiling tool that identifies high-risk markers often missed by conventional testing.
The trial revealed a subgroup of patients who were genetically high-risk but would have been categorized as "standard-risk" under normal circumstances. By utilizing molecular diagnostics to identify this "hidden" group and providing them with personalized, risk-adapted treatment, researchers observed a 62.3% survival rate at six years, compared to just 20.3% for those in the standard-risk category who received conventional treatment.
This finding serves as a powerful indictment of the current diagnostic landscape, where gene expression profiling is not yet a routine part of NHS care. Many patients are currently diagnosed as having "standard-risk" disease, inadvertently depriving them of the aggressive, early intervention that could potentially alter the trajectory of their illness.
Official Perspectives and Expert Analysis
The success of the OPTIMUM trial has resonated across the oncology community, sparking calls for urgent policy updates to incorporate molecular testing into routine clinical practice.
Professor Martin Kaiser, Professor of Molecular Haematology at The Institute of Cancer Research and a Consultant Haematologist at The Royal Marsden, emphasized the transformative potential of the trial: "High-risk myeloma has traditionally been one of the toughest challenges we face… These long-term results show that when we adapt treatment to the biology of the disease, we can significantly extend survival for many patients who previously had very limited options."
Professor Kristian Helin, chief executive of the ICR, echoed these sentiments, framing the study as a cornerstone of the future of cancer care: "By matching treatment to the molecular features of each person’s disease, we are beginning to outsmart cancers that were once extremely difficult to treat. Closing the diagnostic gap will be essential if every patient, wherever they are treated, is to benefit from the kind of tailored care these results make possible."
From the perspective of patient advocacy, Dr. Sophie Castell, CEO of Myeloma UK, noted the practical implications: "We firmly believe that advanced genetic testing and adapting treatment accordingly is the future of myeloma care. Identifying which patients are more likely to benefit from a personalized approach to treatment has been shown to keep myeloma at bay longer and give people a better chance to live well with their disease."
Implications for the Future of Oncology
The implications of the OPTIMUM study are two-fold: they underscore the efficacy of intensive, personalized drug combinations and highlight the necessity of infrastructure for advanced diagnostics.
1. The Need for Universal Molecular Testing
The study proves that diagnostic technology, specifically the MMProfiler SKY92 test, is not merely an academic exercise but a life-saving tool. With the test currently being evaluated through NICE’s diagnostic technology assessment programme, there is a clear path toward potential integration into the NHS. Providing universal access to such testing is the only way to ensure that the "hidden" high-risk patients receive the intensive care they require from the moment of diagnosis.
2. Addressing the "Extremely Complex" Subgroup
Despite the trial’s success, researchers identified a subset of patients with extremely complex genetic profiles—defined by three or more high-risk genetic abnormalities—whose outcomes remained poor despite intensive treatment. This group represents an "unmet clinical need." The authors of the study have urged that these patients be prioritized for trials investigating entirely new classes of treatment, suggesting that for this specific demographic, the current suite of five medicines, while powerful, is not enough.
3. A Shift Toward Precision Medicine
The OPTIMUM trial aligns with the ambitions of the NHS 10-year cancer plan, which emphasizes the shift toward molecularly-guided care. By proving that existing, licensed medicines can be utilized more effectively when directed by genetic intelligence, the trial offers a roadmap that is both clinically and economically sustainable.
A Personal Perspective: The Human Impact
Beyond the data and the clinical terminology, the trial has had a profound impact on individual lives. Ken Theobold, a 76-year-old patient diagnosed with high-risk myeloma in 2018, was initially given a prognosis of only two years. After participating in the MUK Nine trial, he remains an active, thriving individual.
"Joining the trial was an absolute no-brainer," says Theobold. "If there was a chance it could help me and help future patients, I wanted to be part of it." Today, Theobold enjoys travel and time with his five grandchildren—a outcome that would have been unimaginable just a few years ago. His story is a poignant reminder that while research is measured in statistics, its true value is measured in the extra years of life granted to patients and their families.
As the medical community digests these results, the mandate is clear: the integration of genetic profiling into standard care is no longer a luxury, but a necessity. By embracing the principles of precision medicine, the healthcare system can turn the tide on one of the most aggressive forms of blood cancer, ensuring that patients like Ken are the rule rather than the exception.
About the Author
